Michael Vi/iStock Editorial via Getty Images
- AbbVie (NYSE:ABBV) announced Monday that the European Commission cleared its oral Janus Kinase (JAK) inhibitor Rinvoq as a treatment for certain adults with Crohn's disease.
- Accordingly, Rinvoq, also known as upadacitinib, will be available in the region for adults with moderately to severely